{
  "id": 14123403,
  "title": "Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock",
  "url": "https://urgent.news/2026/10/13/stoke-therapeutics-general-counsel-jonathan-allan-sells-16-508-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-13T05:01:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/stoke-therapeutics-general-counsel-jonathan-allan-sells-16508-stock-93CH-4945433"
  },
  "original_language": "en",
  "account": "Stoke Therapeutics' General Counsel and Corporate Secretary, Jonathan Allan, divested $16,508 worth of company shares on October 2nd, 2026. The 627 shares were sold at $26.33 per share after being acquired via a pre-arranged Rule 10b5-1 trading plan established on November 10th, 2025. Notably, Allan now directly owns 20,598 shares of Stoke Therapeutics common stock. Since the October sale, the stock has depreciated, currently trading at $24.15, a decline of approximately 24% for the year. Research suggests the stock may be overvalued compared to its intrinsic value, positioning Stoke Therapeutics among the Most Overvalued stocks. Despite this, analysts remain hopeful, with price targets ranging from $35 to $60, indicating a possible upside of 88% from the present price. More detailed valuation and financial analysis can be found in InvestingPro's Pro Research Report on Stoke Therapeutics and 1,400+ other US equities. Conversely, Stoke Therapeutics reported a mixed quarter in Q2 2026, with adjusted earnings per share coming in at $0.93, below the consensus estimate of $0.77. However, revenue exceeded expectations, reaching $9.33 million compared to the forecasted $5.19 million. This revenue boost is largely due to the progress of their lead Dravet syndrome program, zorevunersen, which is on track for a potential U.S. launch in early 2028. The EMPEROR Phase 3 trial for zorevunersen has reached 162 patients, exceeding the initial target of 150. Notably, Canaccord has reduced its price target for Stoke Therapeutics to $58 from $60 and has maintained a Buy rating, while Goldman Sachs has kept a Buy rating with a $44 price target. The upcoming rolling NDA submission starting in Q1 2027 could further influence the company's future trajectory.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Toast CRO Jonathan Vassil sells $230,168 of company stock",
        "url": "https://urgent.news/2026/10/11/toast-cro-jonathan-vassil-sells-230-168-of-company-stock",
        "published": "2026-10-11T08:46:12.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}